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The overproduction of b-amyloid (Ab) fragments in transgenic APPswe/PS1dE9 mice results in
formation of amyloid deposits in the cerebral cortex and hippocampus starting around four months of
age and leading to cognitive impairment much later. We have previously found an age and transgene-
dependent weakening of muscarinic receptor-mediated transmission that was not present in young
(6e10-week-old) animals but preceded both amyloid deposits and cognitive deﬁcits. Now we
investigated immediate and prolonged in vitro effects of non-aggregated Ab1e42 on coupling of
individual muscarinic receptor subtypes expressed in CHO (Chinese hamster ovary) cells and their
underlying mechanisms. Immediate application of 1 mM Ab1e42 had no effect on the binding of the
muscarinic antagonist N-methylscopolamine or the agonist carbachol. In contrast, 4-day treatment of
CHO cells expressing the M1 muscarinic receptor with 100 nM Ab1e42 signiﬁcantly changed the
binding characteristics of the muscarinic agonist carbachol and reduced the extent of the M1
receptor-stimulated breakdown of phosphatidylinositol while it did not demonstrate overt toxic
effects. The treatment had no inﬂuence on the expression of either G-proteins or muscarinic
receptors. In concert, we found no change in the gene expression of muscarinic receptor subtypes and
gene or protein expression of the Gs, Gq/11, and Gi/o G-proteins in the cerebral cortex of young adult
APPswe/PS1dE9 mice that demonstrate high concentrations of soluble Ab1e42 and impaired musca-
rinic receptor-mediated G-protein activation. Our results provide strong evidence that the initial
injurious effects of Ab1e42 on M1 muscarinic receptor-mediated transmissionis is due to compro-
mised coupling of the receptor with Gq/11 G-protein.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license. 1. Introduction
Alzheimer’s disease (AD) is presently the most widespread
dementing neurodegenerative disease. A major hallmark of the
disease is the presence of amyloid plaques and neuroﬁbrilary
tangles in the cerebral cortex and hippocampus. Studies of familial
cases detected three genes directly linked to the disease and
persuasively pointed to a crucial role of amyloid-b (Ab) fragmentsChinese hamster ovary cells;
cells expressing individual
ptors.
: þ420 296442488.
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-NC-ND license. in the pathogenesis of the disease (Masters et al., 1985a,b; Hardy
and Higgins, 1992; Selkoe, 2001). A general consensus now exists
that an increase in soluble Ab oligomers concentration initiates and
drives the pathology of AD (McLean et al., 1999; Selkoe, 2002;
Glabe, 2006). However, the initial harmful functional effects that
precede clinical manifestation, characteristic amyloid pathology,
and neurodegeneration remain largely unknown. Consistent
damage of cholinergic neurons in the basal forebrain in the
terminal state of AD led to the formulation of the cholinergic
hypothesis of AD (Bartus et al., 1982). Despite doubts about the
general applicability of this hypothesis (Davis et al., 1999; Bartus,
2000; DeKosky et al., 2002), the responsiveness of the disease to
cholinesterase inhibitor therapy supports its viability. It has been
demonstrated that immunolesion of basal forebrain cholinergic
neurons in rats resulting in presynaptic cholinergic deﬁcit alters
APPmetabolism in cerebral cortex (Rossner et al., 1997). In addition,
treatment of Parkinson’s patients with antimuscarinic drugs
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gene knockout in mice increases amyloidogenic metabolism of APP
(Davis et al., 2010).
The development of transgenic mouse models of AD has enabled
studies ondeviations of neuronal functioning in the course of gradual
in vivo increase in the concentration of soluble human Ab fragments
and development of amyloid pathology. The APPswe/PS1dE9 trans-
genic mouse model of AD demonstrates a robust overproduction of
Ab1e42 fragments that ﬁnally leads to the appearance of amyloid
pathology, cognitive decline, and neurodegeneration (Jankowsky
et al., 2004; Savonenko et al., 2005; Liu et al., 2008). In this model
we have previously demonstrated age and transgene-dependent
weakening of muscarinic receptor-mediated G-protein activation.
This reduction was not present in young (6e10-week-old) mice but
was alreadypresent at the timewhen amyloid plaques formation just
started (Machova et al., 2008, 2010).
In the present in vitro experiments we show that prolonged, but
not immediate, treatment of Chinese hamster ovary (CHO) cells
expressing individual muscarinic receptor subtypes with the Ab1e
42 fragment speciﬁcally affects muscarinic M1 receptor/G-protein
interaction. This damage manifests itself as a change in agonist
binding characteristics and reduced efﬁcacy in activating Gq/11 G-
protein signaling. We next tested the hypothesis that reduction in
muscarinic receptor-mediated signal transduction is due to
changes in the expression of receptor/G-protein complex compo-
nents. However, we found no changes in either gene expression of
individual subtypes of muscarinic receptor or gene and protein
expression of major subclasses of their preferential G-proteins in
APPswe/PS1dE9 mice. In accordance, prolonged Ab1e42 treatment
of CHO cells expressing muscarinic receptor subtypes did not
changemembrane concentration of either G-proteins ormuscarinic
receptors. These ﬁndings support the notion that the early func-
tional impairment of muscarinic transmission is likely due to
a change that primarily occurs within the cell membrane and
selectively impacts the M1 receptor/G-protein interaction.
2. Methods
2.1. Experimental animals
The APPswe/PS1dE9 founder mice were obtained from the Johns Hopkins
University, Baltimore, MD, USA (D. Borchelt and J. Jankowsky, Dept. Pathology) and
a colony was established at the University of Eastern Finland at Kuopio Finland as
described previously (Machova et al., 2008). The housing conditions (Laborator-
yAnimal Center, Kuopio, Finland and Animal Facility of the Institute of Physiology,
v.v.i. in Prague, Czech Republic) were controlled (temperature 22 C, light from07:00
to 19:00; humidity 50e60%), and fresh food and water were freely available. Female
transgenic mice and littermate controls were transported to Prague by air and left to
adapt for at least twoweeks before experiments. Two age groups of mice were used,
young (7e10 weeks) and adult (5e7 months). The experiments were conducted
according to the Council of Europe (Directive 86/609) in accordance with the
Declaration of Helsinki.
2.2. Cell cultures and preparation of membranes
Cell culturing and membrane preparation were done essentially as described
earlier (Jakubik et al., 2006). Brieﬂy, Chinese hamster ovary cells stably transfected
with the humanM1 throughM5muscarinic receptor genes (kindly supplied by Prof.
T.I. Bonner) were grown to conﬂuency in 75 cm2 ﬂasks in Dulbecco’s modiﬁed
Eagle’s medium supplemented with 10% fetal bovine serum and 0.01% geneticine to
conﬂuency. Then they were subcultured to sixteen 100-mm Petri dishes. For
experiments on prolonged effects, 100 nM human amyloid b1e42 (Ab1e42; US
Peptides, Rancho Cucamonga, CA) was added to medium next day after subcultur-
ing. Stock solution of Ab1e42 was prepared in redestilled water and stored in aliquots
at20 C. Cells were grown in a CO2 incubator for 5 days without change of medium
(four days in the presence of Ab1e42) and then harvested. For experiments on
immediate effects of Ab1e42 during binding assay, 5 mM sodium butyrate was added
to the culture medium one day before harvesting to increase receptor expression
(levels of receptor expression are shown in Supplementary material Table S2).
Incubation medium was removed; cells were washed with 10 ml of phosphate-
buffered saline (PBS), mechanically released into 5 ml of fresh PBS, and collectedby 3-min centrifugation at 1000  g. Washed cells were diluted in ice-cold
homogenization medium (100 mM NaCl, 20 mM Na-HEPES buffer, and 10 mM
EDTA, pH 7.4) and homogenized on ice by two 30-s strokes in Ultra-Turrax
homogenizer (Janke and Kunkel, Germany) with a 30 s pause between strokes.
Cell homogenate was ﬁrst centrifuged for 3 min at 300 g to remove coarse cell debris
and nuclei. The crude membrane fraction was sedimented for 30 min at 30 000 g at
4 C. The pellet was resuspended in incubation medium (100 mM NaCl, and 20 mM
Na-HEPES buffer, pH 7.4), and centrifuged again under the same conditions. Pellets
were kept at 75 C until assayed for no more than 12 weeks. Membrane protein
content was determined using Peterson’s modiﬁcation of Lowry’s method (Lowry
et al., 1951; Peterson, 1977) with human serum albumin as a standard.
2.3. mRNA expression of muscarinic receptor subtypes and G-proteins a-subunits
Total RNA from about 20 mg of cerebral cortices of 6e10 weeks and 5e6months
old APPswe/PS1dE9 female mice was isolated using RNAwiz (Ambion, UK) and
further processed using DNA-free kit (Ambion, UK). The purity was checked spec-
trophotometrically at 260 nm and 280 nm. Reverse transcription of isolated RNAwas
performed using M-MLV RT (Promega, USA) in accordance with the manufacturer’s
instructions in a ﬁnal volume of 10 ml with 1 mg of isolated RNA and 1 mg of anchored
oligo(dT)23 primers (Sigma, Prague). Primers are listed in Supplementary material
(Table S1). Quantiﬁcation ofmRNAwas done essentially as described (Machova et al.,
2009) using Light Cycler (Roche, USA) and Light Cycler software. Denaturation
analysis was performed to verify the identity of the product. Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was used as an internal standard.
2.4. Western blot and immunodetection of G-protein a-subunits
Separation and detection of membrane proteins was done essentially as
described (Rudajev et al., 2005). Brieﬂy, membranes (40 mg of proteins) were dis-
solved in sodium dodecylsulphate and separated on 13% polyacrylamide gels.
Separated proteins were transferred to nitrocellulose membrane and visualized
using primary antibodies (from Santa Cruz Biotechnology, USA) and secondary HRP-
labeled antibodies and ECL kit (from Pierce, USA).
2.5. Saturation and displacement binding studies
Density and afﬁnity of muscarinic receptors incorporated in CHO cell
membranes (5 mg of membrane proteins for M1 and M3 receptors, and 20 mg of
membrane proteins for M2, M4, and M5 receptors) were determined in saturation
binding experiments with the subtype non-selective muscarinic antagonist [3H]-N-
methyl scopolamine (3H-NMS; GE Healthcare, UK) as described previously (Michal
et al., 2009). Afﬁnity of the agonist carbachol was estimated in displacement
experiments using 1 nM 3H-NMS as a tracer. Non-speciﬁc binding was determined
in the presence of 10 mM atropine. Fast ﬁltration to separate bound and free ligand
was carried out using Uniﬁlter plates (Whatman, USA) and Brandel Harvestor
(Brandel, USA). Plates were dried in vacuum and radioactivity retained on ﬁlters was
determined in Rotiszint (Carl Roth, Germany) using Microbeta scintillation counter
(PerkinElmer Wallac, Finland).
2.6. GTP-g35S binding
Muscarinic receptor-induced activation of G-proteins was determined as an
increase of GTP-g35S binding to membranes induced by the muscarinic receptor
agonist carbachol, essentially as described earlier (Jakubik et al., 2006; Machova
et al., 2008). Brieﬂy, 50 ml aliquots of membranes containing 5e20 mg protein
were ﬁrst incubated for 15 min at 30 C in 150 ml of reaction buffer containing
100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, 1 mM DTT, 40 mM GDP for M2 and M4
receptors or 1 mM GDP for M1 and M3 receptors, and the non-hydrolyzable
acetylcholine analog carbachol at a concentration range 0.15e1000 mM for M1 and
M3 receptors or 0.02e100 mM for M2 and M4 receptors. Afterward 50 ml aliquots of
GTP-g35S (Biotrend Chemikalien, Germany; SRA 1000 Ci/mmol) were added to give
a ﬁnal concentration of 500 pM and incubation continued for another 20 min. Total
content of G-proteins in membranes was determined as GTP-g35S binding in the
absence of GDP. Non-speciﬁc binding was assessed in the presence of 10 mM unla-
beled GTP. Incubation was terminated by rapid vacuum ﬁltration throughWhatman
GF/F ﬁlters using Tomtec Harvester Mach III (USA). Radioactivity retained on ﬁlters
was measured with Wallac Microbeta counter.
2.7. Functional assays in intact cells
Inositol phosphates accumulation induced by carbachol was assayed in attached
cells expressing M1 receptor grown in 24-well-plates essentially as described
previously (Michal et al., 2009). Cells were loaded with 3H-myo-inositol (ARC, USA)
for 3 h, free 3H-myo-inositol was washed off, and the carbachol-induced 3H-inosi-
tolphosphates accumulation was measured in medium containing 10 mM lithium
and respective concentrations of carbachol (0e100 mM) after 5 min lasting incu-
bation at 37 C. Inhibition of forskolin-stimulated cAMP synthesis was measured in
M2 receptor expressing cell suspension in DMEM saturated with 5% CO2/95% O2.
H. Janícková et al. / Neuropharmacology 67 (2013) 272e283274Cells from one 10 cm diameter Petri dish were mechanically released to phosphate-
buffered saline, separated by careful repeated aspiration to a pipette, sedimented at
200  g for 5 min, and supernatant was discarded. The cell pellet was resuspended
in 4 ml DMEM containing 1 mM isobutylmethylxanthine (IBMX) and preincubated
for 5 min at room temperature. One hundred ml aliquots of cell suspension
(approximately 100 mg of proteins) were transferred to prewarmed 100 ml aliquots of
DMEM containing forskolin and relevant concentrations of carbachol (ﬁnal
concentrations during incubationwere 100 mM for IBMX, 10 mM for forskolin and 0e
10 mM for carbachol). Incubation for 10 min at 37 C was stopped by transferring
samples on ice and adding HCl to a ﬁnal 100 mM concentration. Aliquots (100 ml) of
HCl extracts were taken for cAMP determination using Elisa kit (New East Biosci-
ences, USA) according to instructions of the manufacturer. Inﬂuence of prolonged
Ab1e42 treatment on the formation of reactive oxygen intermediates in cells grown
in 24-well-plates was determined using the ﬂuorescence probe 6-carboxy-20 ,70-
dichlorodihydroﬂuorescein diacetate (Molecular Probes, USA) as described earlier
(Novakova et al., 2005).
2.8. Activities of caspase-3 and caspase-8
Activities of caspase-3 and caspase-8 were determined in cell lysates prepared
from cells grown in 24-well-plates ﬂuorometrically using acDVED-AMC and acIETD-
AMC substrates (Sigma, Prague) as described earlier (Novakova et al., 2005).
2.9. Determination of Ab1e42 aggregation
The extent of Ab1e42 aggregation in stock solution (at the beginning of cultiva-
tion) and in cultivation medium after 4-day incubations was determined using thi-
oﬂavineT binding and Western blot. Thioﬂavine binding was estimated inA B
D E
Fig. 1. Immediate and prolonged inﬂuence of Ab1e42 on carbachol binding to individual subt
N-methylscopolamine (3H-NMS) binding in the absence (closed circles) or presence (closed s
and in membranes prepared from cells grown for four days in the presence of 100 nM Ab1e4
of carbachol. AeF: Receptor subtypes are indicated in each graph. D: Displacement of 3H-NM
cells grown in the presence of 100 nM Ab1e42 (squares) performed in the absence (closed sy
number of observations are shown in Table 1.microtitration plates as described by Betts et al. (2008). One hundred microlitre
aliquots of samples were mixed with 100 ml of 200 mM glycine buffer (pH 8.5)
containing 12 mM thioﬂavine T (Sigma Aldrich, Czech Republic). The ﬂuorescence at
485 nm after excitation at 435 nm was determined by plate reader Victor (Perkin
Elmer). Western blot and immunodetection was done after separation on 4e20%
gradient polyacrylamide gel. Separated samples were transferred to nitrocellulose
membrane and assemblies of Ab1e42 were visualized using primary antibodies 4G8
and 6E10 (from Covance, USA) and secondary HRP-labeled antibodies and ECL kit
(from Pierce, USA). For electron microscopy, ﬁve ul drops of Ab1e42 stock solution
(100 mM in water) were applied onto glow-discharge activated carbon-coated grids
(Benada and Pokorny,1990) and let adsorb for 30 s. The grids were thenwashedwith
1% ammonium molybdate and immediately negatively stained with 2% uranyl
acetate in double distilled water for 30 s. The excess of water was blotted with ﬁlter
paper and the grids were air-dried. The samples were examined in a Philips CM100
electron microscope at 80 kV. The images were digitally recorded using MegaViewII
slow scan camera at 64 000 timesmagniﬁcation,which gives pixel size of about 1 nm.2.10. Data treatment and statistical evaluation
Curve ﬁtting and statistical evaluation of datawas done using Prism 5 (GraphPad
Software Inc., CA, USA). Rectangular hyperbolae were ﬁtted to data obtained in
saturation analysis experiments. A sigmoidal concentrationeresponse curve equa-
tion with constant or variable slope as appropriate was ﬁtted to data obtained in
GTP-g35S binding, inositolphosphates accumulation, and cAMP inhibition experi-
ments. A two-sites displacement curve equation was ﬁtted to data obtained in
displacement experiments. Better ﬁts were determined using F-test. The signiﬁ-
cance of differences among groups was tested by Anova and indicated post-hoc
tests, t-test, or paired t-test as appropriate. Results are shown as means  S.E.M.C
F
ypes of muscarinic receptors. Competition of carbachol (abscissa, log M) with 1 nM 3H-
quares) of 1 mM Ab1e42 during binding assay in membranes prepared from control cells,
2 (open squares) is expressed as percentage of control binding (ordinate) in the absence
S binding in M1 receptor expressing membranes prepared from control cells (circles) or
mbols) or presence of GppNHp (open symbols). Parameters of displacement curves and
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3.1. Effects of Ab1e42 on agonist binding to different muscarinic
receptor subtypes
Binding characteristics of themuscarinic agonist carbachol were
determined in displacement experiments using the labeled
muscarinic antagonist 3H-N-methylscopolamine (3H-NMS) as
a tracer. Neither direct addition of 1 mMAb1e42 to the binding assay
buffer in membranes prepared from CHO cells grown in control
medium nor prolonged treatment of cells with 100 nM Ab1e42 for
four days before preparation of membranes inﬂuenced the binding
characteristics of 3H-NMS (see Supplementary material Table S2).
As expected, the displacement of 3H-NMS binding by the
muscarinic agonist carbachol, a non-hydrolyzable analog of acetyl-
choline, demonstrated high- and low-afﬁnity binding sites (Fig. 1,
closed circles; Table 1) at all receptor subtypes. Similar to 3H-NMS
binding, the direct addition of 1 mM Ab1e42 to the binding assay
buffer in displacement experiments had no inﬂuence on binding
parameters of carbachol (Fig.1 and Table 1) at any receptor subtype.
In contrast, prolonged treatment with 100 nM Ab1e42 for four days
changed carbachol binding in membranes prepared from cells
expressing the M1, and to a lesser extent also the M3 receptors but
not the M5 receptors (Fig. 1 and Table 1). Speciﬁcally, prolonged
treatment with Ab1e42 resulted in an increase in the proportion of
agonist high-afﬁnity binding sites at the M1 and the M3 subtypes
(from 0.21 to 0.33, p < 0.01, and 0.20 to 0.38, p < 0.05, respectively)
and a decrease in the afﬁnity of the agonist at the high-afﬁnity
binding site, speciﬁcally at the M1 subtype (Ki-high from 0.15 mM
to 2.1 mM, p< 0.01). Prolonged treatment of M1 receptor expressing
cells with 10 or 1000 nM concentration of Ab1e42 also induced
a decrease in afﬁnity of the agonist at the high-afﬁnity binding site
(to 3.0 and 2.2 mM, respectively; p < 0.01) while an increase in the
proportion of the high-afﬁnity binding sites (to 0.28 and 0.26,
respectively) was not statistically signiﬁcant (Table 1). As expected,
prolonged treatment with 100 nM of the Ab42 scrambled peptideTable 1
Effects of Ab1e42 on parameters of carbachol binding.
Receptor subtype
treatment
Parameter
pKi-high pKi-low fH (n)
M1 control 6.73  0.14 3.91  0.08 0.21  0.02 19
M1 control þ GppNHp e 3.88  0.13 n.a. 3
M1 acute 1 mM Ab 7.08  0.11 3.75  0.18 0.20  0.03 6
M1 four days 10 nM Ab 5.52  0.15b 3.75  0.05 0.28  0.04 5
100 nM Ab 5.68  0.27b 4.07  0.16 0.33  0.03b 8
100 nM scrambled 6.62  0.25 3.90  0.02 0.20  0.03 5
100 nM Ab þGppNHp e 3.83  0.12 n.a. 3
1 mM Ab 5.65  0.01b 3.77  0.04 0.26  0.04 5
M2 control 7.56  0.10 4.96  0.08 0.66  0.03 11
M2 acute 1 mM Ab 7.72  0.09 5.21  0.02 0.66  0.04 4
M2 four days 100 nM Ab 7.60  0.22 4.84  0.19 0.61  0.03 5
M3 control 6.58  0.29 3.93  0.13 0.20  0.02 9
M3 acute 1 mM Ab 6.74  0.36 3.80  0.13 0.20  0.04 6
M3 four days 100 nM Ab 6.01  0.36 4.25  0.05 0.38  0.06a 3
M4 control 7.39  0.05 4.94  0.09 0.46  0.02 7
M4 acute 1 mM Ab 7.36  0.09 4.90  0.13 0.48  0.02 4
M4 four days 100 nM Ab 7.50  0.08 5.10  0.06 0.47  0.01 3
M5 control 6.91  0.15 4.93  0.016 0.49  0.03 8
M5 acute 1 mM Ab 6.81  0.19 5.01  0.08 0.54  0.05 3
M5 four days 100 nM Ab 6.60  0.11 4.57  0.15 0.55  0.06 4
a p < 0.05; signiﬁcantly different from control by one-way Anova followed by
Dunnett’s multiple comparison test.
b p < 0.01; signiﬁcantly different from control by one-way Anova followed by
Dunnett’s multiple comparison test.was without effect (Fig. 1A; Table 1). Uncoupling of M1 receptors by
200 mM of the non-hydrolyzable GTP analog guanosine-50-(bg-
imino)triphosphate (GppNHp) shifted the two-site carbachol
displacement curves to a single-site curvewith a similar low-afﬁnity
in membranes prepared from both control and 100 nM Ab1e42
treated cells (pKi 3.88  0.13 and 3.83  0.12, respectively; n ¼ 3)
(Fig. 1D; Table 1).
3.2. Functional consequences of prolonged Ab1e42 treatment
In subsequent experiments we probed muscarinic receptor-
mediated G-protein activation as carbachol-induced GTP-g35S
binding in membranes prepared from cells subjected to prolonged
treatmentwith 100 nMAb1e42. This treatment did not change either
basal (in the absence of agonist) or total (in the absence ofGDP in the
reaction mixture) binding of GTP-g35S at any receptor subtype (see
Supplementary material; Table S3). Similarly, prolonged Ab1e42
treatment had no effect on the concentrationeresponse curves of
receptor activation at any of the M1 through M4 receptor subtypes
(Fig. 2, Table 2A). However, all curves displayed Hill slopes signiﬁ-
cantly smaller than unity, indicating interactions of muscarinic
receptor subtypes with more than one G-protein over the applied
concentration range of carbachol.
To test more closely for a possible inﬂuence of the treatment on
M1 receptor signaling pathways, we determined M1 receptor-
stimulated inositolphosphates accumulation that is mediated by
M1 preferential Gq/11 G-proteins in intact CHO cells. M2 receptor-
mediated inhibition of forskolin-stimulated cAMP synthesis that
is mediated by Gi/o G-proteins served as a negative control. As
shown in Fig. 3 and Table 2B, prolonged treatment with 100 nM
Ab1e42 reduced the efﬁcacy of M1 receptor-mediated inositol-
phosphates accumulation by about 14% (p < 0.01 by paired t-test,
ﬁve independent experiments in triplicates) while M2 receptor-
mediated inhibition of forskolin-stimulated cAMP synthesis
remained intact (six independent experiments in triplicates).
Attenuation of phosphatidylinositol hydrolysis was not due to
changes in membrane concentrations of labeled phosphatidylino-
sitol (see text to Fig. 3). Similarly, the density of muscarinic receptor
subtypes (see Supplementary material Table S2) or their prefer-
ential G-proteins (Fig. 4) was not changed by the treatment.
Another possible explanation for the observed effects of prolonged
treatment with 100 nM Ab1e42 on attenuation of M1 receptor
signaling is potential general noxious effects of Ab1e42 (Yankner,
1996; Yankner and Lu, 2009). This is unlikely, however, because
four-day treatment of CHO cells with Ab1e42 up to 1 mM concen-
tration had no effect on either caspase-3 or caspase-8 activity
(Fig. 5A and B, respectively), while 10 mM Ab1e42 signiﬁcantly
induced caspase-3 activity. Similarly, an increase in formation of
reactive oxygen intermediates in intact cells became apparent only
at Ab1e42 concentration of 1 mM and above (Fig. 5C).
3.3. Determination of Ab1e42 species in cultivation medium
In the next experiments we determined which molecular forms
of Ab1e42 are present in cultivation media after four days of treat-
ment. As is shown in Fig. 6, using Western blot and immunode-
tection, two different antibodies detected low molecular mass
oligomers both in stock solution of Ab1e42 and in media after 4-day
incubationof Ab1e42 treated CHOcells in culture.We further veriﬁed
this ﬁnding with the help of thioﬂavine binding (Fig. 7). The aggre-
gation of 100 mM stock solution of Ab1e42 in 10 mM HCl for 24 h at
37 C followed by centrifugation at 16 000 g (Stine et al., 2003)
yieldedaggregatedamyloid that contained44%of original peptide in
stock solution. Measurements of serial dilutions of aggregated
amyloid dispersed in supplemented DMEM displayed a linear
A B
C D
Fig. 2. Prolonged Ab1e42 treatment and G-protein activation in CHO cell membranes. Prolonged treatment of CHO-M1 through CHO-M4 cells with 100 nM Ab1e42 has no effect on
carbachol-stimulated GTP-g35S binding. Membranes prepared from control cells (open circles) and cells grown for four days in the presence of 100 nM Ab1e42 (closed circles) were
stimulated by carbachol (abscissa, log M) as described in Methods. AeD: Receptor subtypes are indicated in each graph. The increase in GTP-g35S binding (ordinate) is expressed as
fold increase over resting binding. Parameters of the concentrationeresponse relationship are summarized in Table 2. Basal binding of GTP-g35S is shown in Supplementary material
Table S3.
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signal, and a detection limit between 33 and 100 ng (Fig. 7B). The
soluble (16 000 g supernatant) amyloid as well as the original stock
solution inwater showed only small aggregation signal that became
signiﬁcant at concentrations ranging from 128 mg/ml (211 ng of
thioﬂavine-positive species, i.e. 1.6%) and 26 mg/ml (138 ng of
thioﬂavine-positive species at a concentration of 104 mg/ml, i.e.
1.2%), respectively. In concert with thioﬂavine binding, electron
microscopy analysis of 100 mM Ab1e42 stock solution showed no
amyloid aggregates and only sporadic ﬁbrils (Fig. 7C). After 4-day
incubation of CHO cells in the presence of increasing concentra-
tions of Ab1e42 we found signiﬁcant ﬂuorescence signal only in
medium containing 10 mM Ab1e42 (98 ng of thioﬂavine-positive
species, i.e. 2.2%). We did not detect any signal in media with 0.1e
1 mM Ab1e42 after four days in culture (Fig. 7A).3.4. Muscarinic receptors and G-proteins expression in transgenic
animals
Finally we investigated if gradual in vivo accumulation of soluble
Ab1e42 inﬂuences muscarinic receptor and G-proteins expression.
The mRNA concentration of M1 through M4 muscarinic receptor
subtypes did not differ between wild-type littermate control and
transgenic APPswe/PS1dE9 female mice in the cerebral cortex of
both 6e10-week-old (young) and 5e7-month-old (young adult)
mice. The expression of the M5 subtype mRNA was under the
detection limit in both age groups. Expression of theM1muscarinic
receptor, the most abundant subtype, represented similar propor-
tions of all subtypes in young and young adult animals (51% and
62%, respectively). However, the rank order of abundance of
muscarinic receptor subtypes changed from M1 > M4 > M2 > M3
Table 2
Effects of prolonged treatment with 100 nM Ab1e42 on G-protein activation in
membranes and functional response of M1 and M2 receptor expressing cells.
Receptor subtype
treatment
Parameter
Emax pEC50 Hill slope (n)
A: membranes
GTP-g35S binding (fold of resting)
M1 ctrl 2.20  0.08 4.21  0.05 0.81  0.07a 7
M1 Ab1e42 2.32  0.15 4.23  0.15 0.75  0.08a 6
M2 ctrl 4.67  0.75 6.14  0.04 0.62  0.07a 4
M2 Ab1e42 4.52  0.94 6.21  0.09 0.61  0.05a 4
M3 ctrl 1.93  0.07 4.27  0.06 0.78  0.06a 5
M3 Ab1e42 1.98  0.06 4.23  0.09 0.60  0.05a 5
M4 ctrl 4.59  0.51 5.44  0.09 0.77  0.05a 4
M4 Ab1e42 4.81  0.37 5.58  0.06 0.75  0.04a 4
B: Intact cells
IP accumulation (net increase)
M1 ctrl 34.7  1.8 5.44  0.11 1.00 5
M1 Ab1e42 30.0  2.0b 5.40  0.02 1.00 5
cAMP synthesis (% inhibition)
M2 ctrl 34.5  4.0 6.32  0.28 1.00 6
M2 Ab1e42 33.2  3.7 6.30  0.20 1.00 6
a p < 0.05, signiﬁcantly different from unity by one sample t-test.
b p < 0.01, signiﬁcantly different from control by t-test.
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and B).
Similar to muscarinic receptor subtypes, the mRNA expression
of the a-subunits of both inhibitory (Fig. 8C and D) and stimulatory
(Fig. 8E and F) G-proteins was the same inwild-type and transgenic
animals in both age groups. The rank order of abundance of
stimulatory G-protein a-subunits was G11 > Gq > Gs in both
young and young adult animals, whereas that of inibitory G-protein
a-subunits changed from Gi2 > Go > Gi1 > Gi3 in young mice toFig. 3. Effect of prolonged treatment with Ab1e42 on inositolphosphates (IP’s) accumulation i
were grown in control medium (open circles) or in medium containing 100 nM Ab1e42 (clos
myo-inositol, and concentrationeresponse curves for stimulation by carbachol (abscissa, log
as net increase in percent of loaded radioactivity (ordinate). The treatment with Ab1e42 had
accumulation of inositolphosphates (25.4  1.8 and 24.4  1.0 percent of loaded radioact
experiments). B: Cells were incubated in medium containing phosphodiesterase inhibitor
cAMP synthesis inhibition by carbachol (abscissa, log M) were determined as described in
expressed in percent of control (ordinate). Treatment with Ab1e42 had no effect on forskolin-
mg protein/10 min in control and Ab1e42 treated cells, respectively). The sigmoidal three par
of ﬁts are shown in Table 2.Gi1 > Gi3 > Go > Gi2 in young adult mice. Because we have earlier
observed a decrease in the potency of muscarinic receptor-
mediated G-protein activation in transgenic mice starting at the
age of 5e6 months (Machova et al., 2008, 2010), we also deter-
mined protein expression of a-subunits of major G-protein classes
in cortical membranes. None of the major G-protein classes or the
protein levels of the house-keeping gene Na/K-ATPase differed
between wild-type and transgenic animals at the age of 5e6
months (see Supplementary material Fig. S1).
4. Discussion
Despite decades of intensive research, the exact role of cholin-
ergic neurotransmission in the pathogenesis of Alzheimer’s disease
(AD; Bartus et al., 1982) is still unclear. General malfunction of
postsynaptic cholinergic mechanisms in post mortem AD brain
samples (Roth et al., 1995; Greenwood et al., 1995; Jope et al., 1994,
1997; Shiozaki and Iseki, 2004), as well as correlation of impaired
muscarinic M1 receptor/G-protein coupling with disease severity
(Tsang et al., 2005) are in favor of an involvement of impairment of
muscarinic signaling. However, all these ﬁndings relate to the
advanced or end-state of the disease, which makes it difﬁcult to
discern whether deﬁcits in cholinergic transmission also play
a signiﬁcant role in the early pathogenesis. Since such studies are
difﬁcult to carry out in humans, we employed a transgenic mouse
model of AD to probe integrity of cholinergic transmission during
aging and amyloid accumulation. We found an early reduction of
muscarinic receptor-mediated activation of G-proteins that was not
present in young transgenic animals and developed parallel to
a gradual increase in the concentration of soluble human Ab frag-
ments (Machova et al., 2008, 2010).
The present experiments investigated whether in vitro appli-
cation of non-mutated human Ab1e42 inﬂuence signal transductionn intact CHO-M1cells and inhibition of cAMP synthesis in intact CHO-M2 cells. The cells
ed circles) for four days and then used for experiments. A: Cells were labeled with 3H-
M) were determined. The carbachol-induced increase in IP’s accumulation is expressed
no effect either on inositol loading (132  5 and 141  6 dpm/mg of protein) or basal
ivity in control and treated cells, respectively; mean  S.E.M. from ﬁve independent
and forskolin to stimulate cAMP synthesis, and the concentrationeresponse curves of
Methods. The inhibition of forskolin-stimulated cAMP synthesis during incubations is
stimulated synthesis of cAMP in the absence of carbachol (478  50 and 488  61 pmol/
ameter concentrationeresponse equation was ﬁtted to data in both graphs. Parameters
A B
Fig. 4. Prolonged Ab1e42 treatment and G-protein concentrations in CHO cell membranes. Prolonged treatment with 100 nM Ab1e42 has no effect on the concentration of Gq/11 and
Gi/o G-protein in membranes prepared from K1 and CHO-M1 through CHO-M3 cells. Inserts above columns show representative blots. Membranes prepared from control (C) and
Ab1e42 (Ab) treated cells were used for western blot and immunodetection analysis as described in Methods. Relative density of Gq/11 and Gi/o a-subunits (ordinate; density of bands
of treated membranes is expressed as a fraction of density in control membranes from paired experiments) is shown in A and B graph as indicated. Columns K1 (CHO-K1 cells that
do not express any muscarinic receptor) M1, M2, and M3 represent one, three, two, and one independent experiments, respectively. Open column denoted “pooled” shows average
value of all seven experiments. Error bars where appropriate indicate range of individual values.
H. Janícková et al. / Neuropharmacology 67 (2013) 272e283278across plasma membrane in CHO cells expressing muscarinic
receptor subtypes in isolation. The muscarinic receptor family
comprises ﬁve subtypes (Bonner, 1989; Buckley et al., 1989) of
which M2 and M4 receptors preferentially signal through Gi/o
G-proteins, while M1, M3, and M5 subtypes preferentially employ
Gq/11 G-proteins (Jones et al., 1988; Jones, 1993). We found a selec-
tive impairment of M1 receptor/Gq/11 G-protein coupling after 4-
day treatment of cells with relatively low (100 nM) concentration
of Ab1e42. This detrimental effect was not due to a general Ab1e42
toxicity, because consistent with results in neuronal cell lines
(Huang et al., 1998; Novakova et al., 2005) and primary neurons
(Huang et al., 2000), we observed commonly described toxic effectsA B
Fig. 5. Toxic effects of prolonged Ab1e42 treatment. Cells were exposed to the indicated co
Caspase-3 and caspase-8 activities were determined in cell lysates. Data represent pooled val
experiments on CHO-M2 cells run in hexaplicates that yielded the same results. Control valu
and caspase-8, respectively. C: Production of reactive oxygen species (ROS) in intact cells rep
one experiment on CHO-M2 cells run in hexaplicates that yielded the same results. Contro
values expressed in percent of control (open column) in individual experiments. *, p < 0.0
comparison test.like increased reactive oxygen species or caspase-3 activity only at
concentrations 10e100 times higher. In concert, we did not observe
morphological abnormalities in either living cells using phase
contrast microscopy or nuclear staining of ﬁxed cells (see
Supplementary material Fig. 2S). We found only a small proportion
of amyloid aggregates in stock solution we used, and detectable
thioﬂavine binding only after 4-day incubation of cells in
10 mM Ab1e42. Our results thus support the view that overt cellular
toxicity requires higher concentrations of Ab1e42 to allow formation
of amyloid aggregates.
The abnormal M1 receptor agonist binding after Ab1e42 treat-
ment at 100 nM manifested itself as increased proportion of high-C
ncentration of Ab1e42 (abscissa) for four days and then used for assay. A and B graph:
ues derived from two independent experiments on CHO-M1 cells and two independent
es were 36.9  5.2 and 30.5  3.8 of relative light units/mg protein*60 min for caspase-3
resents pooled values derived from two independent experiments on CHO-M1 cells and
l values were 52.8  5.7 of relative light units/mg protein*60 min. Shown are pooled
5; signiﬁcantly different from all other groups by Anova followed by Tukey’s multiple
AB
C
Fig. 6. Western blot determination of Ab1e42 species in stock solutions and incubation
media after four days of incubation. A: Samples of Ab1e42 in water stock solution (lines
1e3: 2000 ng, 400 ng, and 80 ng in 15 ml of water, respectively) and in incubation
media after four days in culture (lines 4e7: 0 ng/15 ml, 6.75 ng/15 ml, 67.5 ng/15 ml,
67.5 ng/1.5 ml of incubation medium, respectively) were separated on gradient 4e20%
polyacrylamide gel, transferred to nitrocellulose membrane, and visualized using 4G8
antibody. Shown immunoblot includes bottom of wells to check for presence of
amyloid that did not enter the gel. B and C: Samples of Ab1e42 in stock solution (lines
1e3: 50 ng, 100 ng, and 50 ng from another stock solution in 15 ml of water, respec-
tively) and in incubation media after four days in culture (lines 4e7: 0 ng/15 ml,
6.75 ng/15 ml, 67.5 ng/15 ml, and 90 ng/2 ml of incubation medium, respectively) were
separated as above and visualized using 4G8 (B) or 6E10 (C) antibody.
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contrast, ten times higher concentrations of Ab1e42 had no direct
effect on the binding characteristics of either the muscarinic
antagonist N-methylscopolamine or the agonist carbachol.
Increased proportion of high-afﬁnity binding sites were found to
a lesser extent also at M3 receptors but not at the remaining
muscarinic receptor subtypes, including the Gq/11 G-protein
preferring M5 subtype. Low-afﬁnity agonist binding was not
changed at any subtype. Uncoupling of M1 receptors using a non-
hydrolyzable analog of GTP shifted the two-site carbachol binding
curves to the same afﬁnity single-site low-afﬁnity binding curve
irrespective of Ab1e42 treatment. Agonists bind with low-afﬁnity to
free receptors, uncoupled from G-proteins. The lack of Ab1e42
treatment effect on low-afﬁnity binding further indicates the
absence of a direct interaction of Ab1e42 with the M1 receptor. The
high-afﬁnity agonist binding conformation is due to allosteric
interactions of carbachol and the complex of receptor with free or
GDP-liganded G-protein (Abdulaev et al., 2006; Jakubik et al., 2011).
The decrease in afﬁnity and increase in proportion of high-afﬁnity
binding sites evidence that prolonged treatment with Ab1e42
impacts interactions between the receptor and G-protein within
the plasma membrane, downstream of agonist binding.
Despite inﬂuencing agonist binding at M1 receptor, the treat-
ment had no inﬂuence on muscarinic receptor-mediated stimula-
tion of GTP-gS binding. However, carbachol-stimulated GTP-gS
binding displayed a ﬂat concentrationeresponse curve (Hill slope
signiﬁcantly less than unity), indicating activation of more than one
class of G-proteins (Tucek et al., 2002; Michal et al., 2007; Jakubik
et al., 2006, 2011). This complicates accurate detection of the
presumed impairment of M1 receptor-mediated Gq/11 G-protein
activation deduced from increased GTP-gS binding in membranes.
Nonetheless, the observed decrease in carbachol-stimulated ino-
sitolphosphates accumulation supports the view of impaired M1
receptor coupling with Gq/11 G-proteins. The selectivity of pro-
longed Ab1e42 treatment in impairing Gq/11 G-protein signaling was
also supported by the observation of unimpaired M2 receptor/Gi/o
G-protein-mediated inhibition of cAMP accumulation in intact
cells, in agreement with intact Gi/o G-protein-mediated auto-
inhibition of acetylcholine release in cortical slices from transgenic
mice (Machova et al., 2010). The speciﬁc effect of Ab onM1 receptor
coupling is further evidenced by the differential inﬂuence on the
binding characteristics at other receptor subtypes and the lack of
effect of the scrambled peptide on the M1 receptor.
A conceivable explanation for the compromised muscarinic
receptor signaling would be a reduced membrane concentration of
G-proteins that are an integral part of the signal transduction
apparatus. However, a prolonged Ab1e42 treatment of CHO cells did
not change membrane concentration of G-proteins. Similarly, in
line with current literature on human brain (McLaughlin et al.,
1991; Jope et al., 1994; Wang and Friedman, 1994; Greenwood
et al., 1995; Muma et al., 2003; Hashimoto et al., 2004), we found
no changes in membrane G-protein concentrations or gene
expression of major G-protein classes in the cerebral cortex of 5e6-
month-old transgenic APPswe/PS1dE9 mice that at this age already
demonstrate a signiﬁcant attenuation of muscarinic receptor-
mediated G-protein activation (Machova et al., 2008).
Disorders of many G-protein coupled receptors are habitually
found at autopsy in veriﬁed AD, which points to their contribution
to AD pathogenesis (for review see Thathiah and De Strooper, 2011).
An interesting explanation of impaired receptor/G-protein-
mediated signaling in transgenic mouse models of AD is Gq/11 G-
protein buffering by oligomerized angiotensin AT2 receptors
(AbdAlla et al., 2009a,b). This potential mechanism, however, does
not seem to explain our ﬁndings, because the prolonged treatment
with 100 nM Ab1e42 did not induce oxidative stress that triggers
AB
C
Fig. 7. Determination of Ab1e42 aggregation using thioﬂavine T binding and electron
microscopy. Thioﬂavine T binding in media after four days in culture. A: Thioﬂavine
binding in 100 ml aliquots of cultivation mediumwithout or with 0.1, 1, and 10 mM Ab1e
42 after 4-day incubation of CHO-M1 and CHO-M2 is shown as fold increase over
control (ordinate) in ﬂuorescence (450 nm excitation, 488 nm emission). Values are
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AT2-receptors (Feng et al., 2005). Dysregulation of the signaling
pathway activated by Gq/11 G-proteins have been suggested to play
a role in AD (for review see Bothmer and Jolles, 1994; Fowler et al.,
1996). Non-toxic concentrations of Ab fragments in vitro have been
shown to affect distant targets like inositolphosphate receptors
(Cowburn et al., 1995; Kurumatani et al., 1998), intracellular
calcium levels (Huang et al., 1998), inositol(1,4,5)-trisphosphate-5-
phosphatase activity (Ronnback and Fowler, 2000) or choline
transport via protein kinase C pathway (Novakova et al., 2005). A
direct effect of Ab fragments on tachykinine receptor and synergy of
its activation with glutamate signaling has also been demonstrated
(Kimura and Schubert, 1993). In binding and functional experi-
ments we investigated the interaction of muscarinic receptors with
G-protein and the formation of second messengers by enzymes
incorporated in the cell membrane. The observed reduction of
phosphatidylinositol hydrolysis could have derived from decreased
availability of the labeled substrate. This seems unlikely, however,
because Ab1e42 had no effect on the labeling of cells with myo-
inositol. A direct inhibition of phospholipase C activity is also an
unlikely explanation, since we found no difference in the basal
inositolphosphates accumulation between control and treated cells
as we would expect in case of phospholipase C inhibition. The lack
of prolonged treatment with Ab1e42 on phospholipase C activity
also supports the observation on primary cortical neurons
demonstrating inhibition of intracellular calcium mobilization by
carbachol but not by stimulation of metabotropic glutamate
receptor (Huang et al., 2000).
Numerous studies have failed to ﬁnd a correlation between the
degree of cognitive decline and the number of amyloid plaques in
post mortem samples (e.g. Nagy et al., 1995). However, the cognitive
decline in AD has been demonstrated to correlate with post mortem
levels of soluble Ab x-40 and x-42 fragments in the cerebral cortex
preceding clear tau pathology (Naslund et al., 2000). On the other
hand, a decline in the presynaptic cholinergic marker choline
acetyltransferase that correlates with both neuritic plaques and
neuroﬁbrillary tangles densities are observed only in advanced
stages of the disease (Davis et al., 1999). This observation speaks for
a rather late damage of cholinergic transmission in the course of the
disease. In contrast, another recent study reported impaired M1
muscarinic receptor/G-protein coupling that correlates with
severity of dementia, thus favoring the contention of an early
postsynaptic malfunction of cholinergic transmission (Tsang et al.,
2005). Our results support the view that the increase in soluble
Ab fragments results in the attenuation of M1 receptor-mediated
signaling that may underlie the early functional deﬁcits and
further drive Ab production (Buxbaum et al., 1992; Nitsch et al.,
1992, 2000; Rossner et al., 1997; Caccamo et al., 2006; Medeiros
et al., 2011). Indeed, pharmacological reduction of Ab level
reverses behavioral deﬁcits and disorders of piriform cortex ﬁeld
potentials in APPswe/PS1dE9 mice (Cramer et al., 2012).
In summary, we demonstrate that prolonged in vitro Ab1e42
treatment of CHO cells expressing M1 muscarinic receptors
changes characteristics of agonist binding and attenuates agonist-means of eight samples from two independent seedings. B: Concentrationeresponse
relationship of thioﬂavine ﬂuorescence in stock solution of Ab1e42 (open squares), and
pellet (open circles) or supernatant (closed circles) prepared from 100 mM Ab1e42 stock
solution incubated for one day in 10 mM HCl at 37 C by centrifugation at 16 000 g for
15 min. All samples were diluted in supplemented DMEM. The increase in thioﬂavine
ﬂuorescence shown as fold increase (ordinate) over control (DMEM alone) is plotted
against Ab1e42 concentration in ng per sample (abscissa, logarithmic scale). Points are
means from quadruplicates. *, p < 0.05, ***, p < 0.001; signiﬁcantly different from
control by one-way Anova followed by Dunnett’s multiple comparison test. C: Electron
microscopy analysis of 100 mM Ab1e42 stock solution shows only sporadic ﬁbrils and no
amyloid aggregates. Scale bar 200 nm.
A B
C D
E F
Fig. 8. Gene expression of muscarinic receptors subtypes and G-protein a-subunits in temporal cortex of control and APPswe/PS1dE9 transgenic mice. The concentration of mRNA
in transgenic mice (black columns) and control littermate mice (open columns) was determined in young (6e10-week-old; A, C, E) and young adult (5e6-month-old; B, D, F)
animals as described in Methods. The expression of any of the tested genes (ordinate, arbitrary units corrected for expression of house-keeping gene GAPDH) differs between age-
matched control and transgenic animals. Abbreviations: wt, wild-type; tg, transgenic; AeB: M1 through M4, subtypes of muscarinic receptors; CeD: Go, Gi1, Gi2, Gi3, a-subunits of
inhibitory Gi/o G-proteins; EeF: G11, Gq, Gs, a-subunits of stimulatory Gq/11- and Gs G-proteins. Results are mean  SEM of values obtained from 5 (muscarinic receptors and G-
proteins in young animals and muscarinic receptors in young adult animals) or 7 (G-proteins in young adult animals) animals.
H. Janícková et al. / Neuropharmacology 67 (2013) 272e283 281induced activation of phosphatidylinositol signaling. This effect, in
linewith the notion of the early involvement in pathogenesis of AD,
is apparently mediated by low molecular mass Ab1e42 species. In
concert with in vivo results, the treatment does not induce either
changes in the expression of major G-proteins, and does not induce
oxidative stress or cytotoxicity. These results implicate that the
noxious effects of Ab1e42 on M1 receptor-mediated transmission
involve a mechanism that develops within the plasma membrane
and impacts receptor/G-protein/phospholipase C interaction.
However, detection of speciﬁc responsible molecular mechanisms
will need further investigation. The attenuation of muscarinic
receptor signaling previously reported in a rather early stage of
amyloid overproduction in a transgenic mouse model of AD
(Machova et al., 2008, 2010) and the demonstration of M1 receptor-
mediated signaling attenuation induced by generally non-toxicconcentrations of Ab1e42 in vitro evidence the important role of
the M1 muscarinic transmission in early pathogenesis of AD.
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